To increase the potency of human papillomavirus (HPV) DNA vaccines, we constructed a series of HPV16 L1 vaccines genetically fused with a secretion signal and/or immune cell-recruiting RANTES. The DNA vaccines encoding secretory HPV L1 were constructed by inserting HPV L1 gene into a vector with an ER-targeting secretory signal sequence. The expression plasmid encoding secretory HPV L1 (pER/L1) was fused with cDNA of RANTES, generating pER/L1/R. For comparison, HPV L1 genes were cloned into pVAX1 vector with no signal sequence (pL1), and further linked to the N-terminus (pL1/R) or C-terminus of RANTES (pR/L1). The secretion of L1 proteins was observed in the pER/L1, pER/L1/R, and pR/L1-transfected cells, except the pL1/R-transfected group. Cytoplasmic localization of L1 protein was observed in the cells transfected with pL1/R, but not with pER/L1/R at 48 h after transfection. In mice, RANTES-fused vaccines more effectively elicited the levels of HPV16 L1-specific IgG and IgG2a antibodies than pL1. Of RANTES-fused vaccines, pER/L1/R encoding the secreted fusion protein induced the highest humoral and CD8 + Tcell-stimulating responses. These results suggest that the immunogenicity of HPV L1 DNA vaccines could be enhanced by genetic fusion to a chemokine and secretory signal peptide sequences.
Introduction
Human papillomavirus (HPV) has been considered the most dominant risk factor in the tumorigenesis of cervical carcinoma, the number one cause of female cancer mortality in developing countries. 1, 2 Of various types of HPV, the high-risk HPV types such as 16 and 18 are known to be more often associated with malignant cervical carcinoma in humans. The development of a vaccine to induce the humoral and cellular immunity against high-risk HPV type may therefore be an efficient means to reduce the incidence of cervical carcinoma.
Given the clinical significance of HPV infection, there have been approaches to develop high-risk HPV-type DNA vaccines. Parenteral immunization with a plasmid DNA expressing the HPV16 L1 major capsid proteins has been reported to induce systemic antibodies and cytotoxic T-lymphocyte responses. 3 Despite significant progress, the immunogenicity of HPV DNA vaccines still needs to be improved. One of the factors for the low efficacy of intramuscularly administered DNA vaccines could be the expression of DNA vaccines in the muscle cells lacking immune costimulatory molecules such as B7. 4 Moreover, the cytoplasmic localization of the expressed antigen proteins in the muscle cells could limit the exposure of antigens to the professional immune cells. 5 To overcome such problems, it might be desirable to develop new genetic immunization systems that can allow the cellular secretion of the HPV antigen proteins after expression, and the targeting of the secreted proteins to the immune cells.
The fusion of an immune cell-recruiting agent to HPV antigen might be one way to deliver the antigen to the immune system. Boyle et al 6 reported the enhanced responses to a DNA vaccine encoding a fusion antigen that was directed to sites of immune induction. Recently, plasmid DNA of immune cell-recruiting chemokines has been studied as molecular adjuvants of DNA vaccines. A previous study demonstrated that genetic fusion of chemokines to a self-tumor antigen could induce protective and T-cell-dependent antitumor immunity. 7 In this study, to enhance the immunogenicity of HPV DNA vaccines, a series of HPV16 L1 genetic fusion vaccines were constructed. We tested whether the immunogenicity of DNA vaccines could be improved by fusion with chemokine RANTES (regulated on activation normal T-cell expressed and secreted), and if so, whether the immunogenicity could be affected by the cellular fate after expression and by the fusion pattern. Of various chemokines, RANTES has been used in this study since the major receptors of RANTES, CCR1, and CCR5 8, 9 have been known to mediate endocytosis important for intracellular delivery and processing of secreted chemokine-fused antigen. We report here the enhanced humoral immune responses and CD8 + T-cell stimulating effects of HPV16 L1 DNA vaccine encoding an endoplasmic reticulum (ER)-targeting secretion signal peptide sequence in the upstream of L1 gene and RANTES in the downstream.
Results
Expression and secretion of HPV16 L1 and chemokine fusion proteins Series of HPV16 L1 DNA vaccines were constructed by simple insertion of gene fragments or by insertion of digested polymerase chain reaction products ( Figure 1 , Table 1 ). All the plasmid DNA constructs encoding HPV16 L1 showed the expression of HPV L1 proteins. However, the fusion of genetic antigen to RANTES and/ or to an ER-targeting secretion signal affected the molecular sizes and the cellular fates of proteins. Empty pVAX1 vector, used as a control, did not show the expression of HPV16 L1 in C2C12 cells after transfection. As shown in Figure 2a , the expression of L1 protein was detected in the pellets of the cells transfected with plasmid DNA encoding HPV16 L1 gene alone (58 kDa). When the cells were transfected with plasmid DNAs encoding both L1 and RANTES (pR/L1, pL1/R, or pER/ L1/R), L1 bands were detected at the higher molecular weight (66 kDa) in the Western blot. The secretion of L1 protein was observed in the supernatants of the cells transfected with pER/L1, pER/L1/R, or pR/L1 ( Figure  2b ). Expression of RANTES was observed in the cells transfected with the plasmid DNAs encoding RANTES such as pR/L1, pL1/R, and pER/L1/R (Figure 2c ). The cellular secretion of RANTES was detected in pR/L1 and pER/L1/R, but not in pL1/R (Figure 2d ).
In line with the Western blot results, the immunofluorescence study indicated that the presence of an ER-targeting signal peptide sequence in the expression vector affected the trafficking of expressed proteins in the cells. At 6 h after transfection, pL1/R and pER/L1/R showed the retention of expressed proteins inside the cells (Figure 3a and b) . However, the cellular fates of expressed proteins were different for pL1/R and pER/ L1/R at 48 h after transfection. The cells transfected with pL1/R clearly showed the immunofluorescence of HPV16 L1 proteins in the cytoplasm (Figure 3c ), whereas the cells transfected with pER/L1/R displayed little immunofluorescence (Figure 3d ).
Humoral immune responses to HPV16 L1 genetic fusion vaccines
The induction of HPV16 L1-specific antibodies was affected by the genetic fusion of HPV16 L1 with RANTES, and by the cellular fate of expressed proteins. Figure 4a shows that the serum levels of IgG antibodies were significantly higher in the mice treated with pER/ L1/R than with pER/L1, indicating the adjuvant effect of genetically fused RANTES. Moreover, the higher levels of IgG were observed in pER/L1 encoding secretory HPV L1 as compared with pL1 lacking the ER-targeting secretory signal peptide sequence. Among RANTESfusion vaccines (pER/L1/R, pL1/R, pR/L1), the induction of IgG responses was higher in pER/L1/R as compared to pL1/R (Figure 4b ). Moreover, the DNA vaccines expressing the secreted HPV L1 protein in fused form, pER/L1/R and pR/L1, differed in the humoral responses, indicating that the humoral immune responses were also affected by the fusion pattern. The coadministration of pL1 and pR revealed IgG levels lower than pER/L1/R. (Table 1) , digested with BglII and NotI, respectively, and inserted into the BglII/NotI sites of pVAX1 vector. RANTES cDNA in pBluescript vector was then amplified using primers C and D, cut with NotI, and inserted into the NotI site of L1 in pVAX1 vector. (d) HPV16 L1 gene was amplified from pGEM-T/L1 using primers G and H, cut with HindIII and BglII, and inserted between HindIII and BglII sites of pVAX1 vector. Next, cDNA of RANTES was amplified using primers E and F, digested with HindIII, and inserted into the HindIII site of L1 in pVAX1 vector. (e) For pER/L1 encoding the secreted HPV L1 protein, HPV16 L1 gene fragments were amplified from pVAX/L1 using primers I and B, cut with XhoI and NotI, then inserted into the XhoI/NotI sites of the polylinker region, located in the 22-bp downstream of the secretion signal sequence of pCMV/myc/ER vector (Invitrogen) with the cytomegalovirus early promoter/enhancer sequence and an ER-targeting 19-amino-acid secretory signal peptide sequence in the backbone. (f) cDNA of RANTES was amplified using primers C and D, digested with NotI, and inserted into the NotI site of pER/L1, generating pER/L1/R.
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The genetic vaccines tested in this study induced the higher levels of IgG2a than IgG1. The HPV L1 genetic vaccine with an ER-targeting secretion signal sequence, pER/L1, produced higher levels of IgG2a and IgG1 relative to the cytoplasmic DNA vaccine, pL1 (Figure 4c ). Of RANTES-fusion vaccines, pER/L1/R showed the higher IgG1 and IgG2a levels than did others such as pR/L1 and pL1/R (Figure 4c ).
CD8
+ T-cell-stimulating effects of HPV16 L1 genetic fusion vaccines
Similar to the humoral immune responses, the CD8 + Tcell-stimulating effects of HPV L1 DNA vaccines were influenced by fusion with RANTES, the cellular fate of expressed vaccine proteins, and the fusion pattern. All the DNA vaccines expressing HPV L1 fused to RANTES (pL1/R, pR/L1, and pER/L1/R) displayed the significantly higher CD8 + T-cell-stimulating activity relative to pL1 encoding L1 alone ( Figure 5 ). The DNA vaccines expressing the secretory HPV L1 showed the higher CD8 + T-cell-stimulating effects than did the other vaccines encoding cytoplasmic HPV L1. Between the DNA vaccines encoding HPV16 L1 alone, pER/L1 showed the higher CD8 + T-cell-stimulating activity than did pL1. Among RANTES-fusion vaccines, the CD8 + Tcell-stimulating activity was the highest in pER/L1/R followed by pR/L1 and pL1/R. pER/L1/R, where L1 was fused to the N-terminus of RANTES, showed the higher CD8 + T-cell-stimulating activity than did pR/L1, where L1 was fused to the C-terminus of RANTES. The coadministration of pL1 and pR, induced the cellular immune responses comparable with pL1/R, but displayed lower effects than did pER/L1/R.
Discussion
In this study, we demonstrated that the genetic fusion with chemokine RANTES could enhance the immunogenicity of HPV16 DNA vaccines. Moreover, our results indicate the importance of cellular fate and fusion pattern in the immunogenicity of genetic fusion vaccines.
The Western blots and immunofluorescence data confirmed that the cellular fates of DNA vaccines could be altered by the presence of an ER-targeting secretion signal peptide sequence. The secretion of RANTES-fused HPV16 L1 protein was observed in the cells transfected with pER/L1/R and pR/L1, but not with pL1/R ( Figure  2 ). The cellular secretion of HPV16 L1 protein expressed from pR/L1 in pVAX1 vector backbone could be expected because of the native 23-amino-acid signal peptide sequence in RANTES. The lack of HPV16 L1 secretion in pL1/R-transfected cell supernatants indicates that the native secretion signal sequence of RANTES genetically fused to the C-terminus of HPV16 L1 lost the ER-targeting secretion pathway, resulting in the cytoplasmic expression of HPV16 L1/RANTES fusion proteins. The lack of immunofluorescence ,d) after transfection, the cells were fixed at room temperature for 20 min using a modified paraformaldehyde-lysine-periodate fixative. 10 Next, the cells were washed, permeabilized for 20 s using cold methanol, and incubated for 2 h with mouse anti-HPV16 L1 CamVir-1 monoclonal antibody (1:250, RDI). The cells were then incubated with fluorescein-conjugated secondary antibody and observed under a fluorescence microscope (Nikon H-III, Japan). Experiment was repeated three times with similar results. Scale bar: 10 mm. The humoral immunogenicity of HPV16 L1 DNA vaccines was enhanced by genetic fusion with RANTES. The stronger IgG levels of pER/L1/R in comparison with pER/L1 imply that the genetic fusion of HPV16 L1 antigen to RANTES might be more effective in inducing humoral immune responses. Previously, the increased humoral antibody responses were observed after treatment with RANTES. 13 It has been suggested that RANTES may enhance the humoral antibody responses through the induction of cytokine and costimulatory molecules, and through the expression of cytokine receptors on T lymphocytes.
In addition to genetic fusion with RANTES chemokine genes, the cellular fates and fusion patterns appear to play a role as important factors affecting the immunogenicity of genetic vaccines. Although pR/L1, pL1/R, and pER/L1/R are all encoding HPV16 L1 genetically fused to RANTES, the higher humoral responses of pER/ L1/R and pR/L1 over pL1/R indicate that the presence of an ER-targeting secretion signal sequence might need to be required for a higher potency of DNA fusion vaccines. Similarly, the higher immune response of secretory pER/L1 in comparison with pL1 indicates the importance of cellular localization in the potency of DNA vaccines. Consistent with our observation, Boyle et al 5 reported that cytotoxic T-lymphocyte and antibody responses were suboptimal when the cellular location of antigen was cytoplasmic after intramuscular DNA immunization. Improvement of humoral and cellular immune responses was reported when the plasmid DNA encoding the outer surface protein C of Borrelia burgdorferi was fused to the native ER-targeting secretory signal sequences of tissue plasminogen activator. 14 We observed the highest IgG induction in the groups immunized with pER/L1/R. RANTES has been reported to be endocytosed via receptors on dendritic cells and monocytes. 8 It is speculated that the secreted fusion proteins of HPV16 L1 and RANTES might be taken up by antigen-presenting cells through chemokine receptors such as CCR1 and CCR5. Recently, RANTES has been IgG and subtype antibody responses to DNA vaccines. For immunization, female BALB/c mice were supplied from Seoul National University animal center (Seoul, Korea). The mice were used at 6-8 weeks of age and received food and water ad libitum. Each mouse was given intramuscular injections into the left quadriceps at a dose of 100 mg of plasmid DNA in 20 ml of phosphate-buffered saline. All mice were boosted with equal doses after 4 and 8 weeks from the first injection. The blood was collected from the tail vein, and the serum levels of anti-HPV16 L1 IgG antibodies (a, b) and IgG1 and IgG2a subtype antibodies (c) were determined by ELISA using HPV16 L1 proteins. 11 The results are expressed as the mean7s.e. (n¼5). RANTES-mediated chemokine amplification in dendritic cells may also shape the microenvironment, potentially enhancing the immune responses to RANTES-fused HPV16 L1 antigen. Currently, the mechanisms by which pER/L1/R exerted the higher immunogenicity than did pR/L1 remain to be elucidated. Sadeghi and co-workers reported that human insulin B-chain genetically fused to the C-terminus of a cholera toxin B could bind to the receptor GM1 ganglioside, whereas N-terminus-fused protein lost the receptor binding structure. 16 The specific residues of RANTES have been shown to affect the binding of RANTES to the receptors such as CCR 1, 3, and 5. 17 The possibility thus exists that the L1 proteins expressed from pER/L1/R could have a favorable conformation for binding of the secreted fusion proteins onto CC chemokine receptors. Moreover, given that the strength of protein secretion and expression could depend on the native secretory signal peptide sequences, 18 we cannot exclude the possibility that the difference in the secretion signal peptide sequences between pER/L1/R and pR/L1 might influence the secretion efficiency of fusion protein to extracellular environments.
The genetic fusion with RANTES chemokine also increased the antigen-specific CD8 + T-cell-stimulating effects of HPV16 L1 DNA vaccines. The higher number of HPV16 L1-specific CD8 + T cells in pER/L1/R over pER/L1 supports the adjuvant role of RANTES in the induction of cellular immune responses. Previously, the induction of cell-mediated antitumor immunity was reported for lymphoma-specific single-chain antigen genetically fused to chemokines such as monocyte chemotactic protein-3 or interferon inducible protein-10.
7 DNA vaccines encoding RANTES were also shown to enhance CD4 + T-cell-mediated protective immunity against herpes simplex virus type 2. 19 The enhanced immunogenicity of secretory HPV16 L1 vaccines genetically fused to RANTES might be applied to develop other HPV genetic vaccines. Although HPV16 is one of the high-risk HPV types associated with cervical carcinomas, there are other high-risk HPV types such as HPV 18 and 33. 20 The genetic fusion of other high-risk HPV-type antigens to RANTES and the administration of multivalent HPV DNA vaccines might be a promising and convenient way to prevent the development of cervical carcinoma in the future. 
